perlolyrine has been researched along with avanafil in 1 studies
| Studies (perlolyrine) | Trials (perlolyrine) | Recent Studies (post-2010) (perlolyrine) | Studies (avanafil) | Trials (avanafil) | Recent Studies (post-2010) (avanafil) |
|---|---|---|---|---|---|
| 15 | 0 | 7 | 68 | 14 | 63 |
| Protein | Taxonomy | perlolyrine (IC50) | avanafil (IC50) |
|---|---|---|---|
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 5.2 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Canis lupus familiaris (dog) | 0.0052 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, C; Jiang, Y; Lou, H; Qiao, Y; Sun, B; Tan, J; Wu, Y; Xie, Z; Zhao, S; Zheng, H | 1 |
1 other study(ies) available for perlolyrine and avanafil
| Article | Year |
|---|---|
Discovery of furyl/thienyl β-carboline derivatives as potent and selective PDE5 inhibitors with excellent vasorelaxant effect.
Topics: Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Female; Humans; Male; Mesenteric Arteries; Molecular Docking Simulation; Phosphodiesterase 5 Inhibitors; Rats, Wistar; Structure-Activity Relationship; Vasodilator Agents | 2018 |